Antimicrobial activity of rhodanine-3-acetic acid derivatives

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F17%3A10365375" target="_blank" >RIV/00216208:11160/17:10365375 - isvavai.cz</a>
Alternative codes found
RIV/71009396:_____/17:N0000002
Result on the web
<a href="http://www.sciencedirect.com/science/article/pii/S0968089616308914" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0968089616308914</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.bmc.2017.01.045" target="_blank" >10.1016/j.bmc.2017.01.045</a>

Result language
angličtina
Original language name
Antimicrobial activity of rhodanine-3-acetic acid derivatives
Original language description
Twenty-four 2-(4-oxo-2-thioxothiazolidin-3-yl)acetic acid (rhodanine-3-acetic acid)-based amides, esters and 5-arylalkylidene derivatives were synthesized, characterized and evaluated as potential antimicrobial agents against a panel of bacteria, mycobacteria and fungi. All of the derivatives were active against mycobacteria. N-(4-Chlorophenyl)-2-[5-(2-hydroxybenzylidene)-4-oxo-2-thioxothiazolidin-3-yl] acetamide demonstrated the highest activity against Mycobacterium tuberculosis with minimum inhibitory concentrations (MIC) of 8-16 mu M. Non-tuberculous mycobacteria were the most susceptible to 2-[5-(2-hydroxybenzylidene)-4-oxo-2-thioxothiazolidin-3-yl]acetic acids (MIC values >= 32 mu M). The highest antibacterial activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus exhibited 4-(trifluoromethyl)phenyl 2-(4-oxo-2-thioxothiazolidin-3-yl)acetate (MIC >= 15.62 mu M). Several structure-activity relationships were identified. The activity against Gram-negative and fungal pathogens was marginal.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy

Project
<a href="/en/project/GJ17-27514Y" target="_blank" >GJ17-27514Y: Peptide Drug Delivery Systems Targeting Macrophages for Antimycobacterial Active Compounds</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)